1. 4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment. Issue 1 (23rd March 2023) Authors: Macía-Rivas, L; Fernández-Laguna, CL; Álvarez-Manceñido, FJ; Arias-Martínez, A; Martínez-Torrón, A; Macías-Declara, I; Cano-Cano, JM; Diez, M; Custodio, A; López-Robles, J; Lozano-Blázquez, A Journal: European journal of hospital pharmacy Issue: Volume 30:Issue 1(2023)supplement 1 Page Start: A96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗